Archive
559 articles, sorted by publication time.
A large evidence review links nicotine e-cigarettes more directly to the risk of lung cancer and oral cancer; it does not amount to claiming that e-cigarettes and conventional cigarettes are equally dangerous, but it weakens the popular idea of a “harmless alternative.”
A shared challenge in Alzheimer’s disease and Parkinson’s disease is not only that harmful proteins clump together, but how cells steer those aggregates toward disaster or function. New research suggests that tubulin may act as a key traffic director, though it remains some distance from becoming a drug.
Firefly Bio puts protein degradation and antibody guidance into the same drug concept; it remains an early-stage platform, but it shows that large pharmaceutical companies are pushing their bets on next-generation cancer therapy toward more precise and more complex molecular engineering.
DePuy Synthes brings AI-assisted image interpretation into the total hip arthroplasty workflow, with the goal not of replacing surgeons, but of making key anatomical landmarks more consistent and the surgical rhythm more predictable.
For a rapidly progressing blood cancer with very few patients and limited treatment options, this approval is more than an addition to the drug list; it also shows antibody-drug conjugates moving further into the blood cancer treatment landscape.
A once-daily oral drug has widened the gap with chemotherapy in an advanced pancreatic cancer trial; the real new question has shifted from whether KRAS can be targeted to which patients can receive it early and how long the benefit can last.
The FDA’s new approval allows HYMPAVZI to reach more patients with hemophilia A and B, from adolescents and adults with inhibitors to children aged 6 to 11; but behind the convenience of a long-acting option, thrombotic risk and real-world care conditions still must be weighed together.
A randomized trial puts middle meningeal artery embolization through more rigorous clinical testing; the results support it as an adjunctive option to standard care, but eligible patients, long-term safety, and practical implementation still require close reading.
An antitumor candidate natural product that appears only in trace amounts in a few tropical plants has long been stuck at the bottleneck of being “too scarce and too difficult to make.” Teams from UBC Okanagan and the University of Florida have identified two enzymes that shape its three-dimensional structure, offering a clearer route for obtaining this class of molecules through biological manufacturing in the future.
A postharvest physiology study focuses on the 24 days after mangoes leave the tree: not freezing the fruit, but keeping it at a temperature cool enough, yet not so cold as to cause chilling injury, so that cells, antioxidant systems, and flavor quality can last longer.
A genetic study of nearly 500 feline tumors shows that cancer in domestic cats is not an island of veterinary medicine; from mammary tumors to skin cancer, cats share some cancer-driving pathways with humans and dogs, offering a reference closer to the natural course of disease for new drug exploration and cross-species cancer research.
A University of Michigan team proposes that many mutations may once have been beneficial, but the environment changed too quickly, causing them to lose their advantage before they could become fixed; this does not overturn evolutionary theory, but instead places natural selection back into a more turbulent world.